How BPC-157 Affects ALT

BPC-157 (body-protective compound 157) is a synthetic pentadecapeptide derived from a sequence in human gastric juice. Its hepatoprotective signal is well-documented in rats but has never been replicated in a controlled human trial.

Preclinical evidence (rat models):

• Sikiric et al., 1993 (PMID 7901724) demonstrated protection against liver lesions induced by restraint stress, bile duct and hepatic artery ligation, and CCl4 administration. ALT reductions of 40-60% versus model controls were reported across the three injury models.
• Proposed mechanisms include NO-system modulation, VEGFR2-mediated angiogenesis (Hsieh et al., 2017, PMID 27847966), upregulation of cytoprotective prostaglandins, and stabilisation of hepatocyte membranes during ischaemia-reperfusion injury.
• The signal is consistent across multiple Sikiric group publications spanning three decades, but every published study is in rodents.

Human evidence:

• Lee & Burgess, 2025 (PMID 40131143) is the only published human safety pilot: 2 subjects, 20 mg IV, no measurable change in hepatic biomarkers (ALT, AST, GGT, bilirubin).
• No published RCT has measured ALT response to oral, subcutaneous, or intramuscular BPC-157 at any dose, in any population.
• The "hepatoprotection in humans" claim that vendors repeat is mechanistic extrapolation, not evidence.

For athletes on a BPC-157 plus AAS stack: the theoretical case is that BPC-157 might blunt 17-alpha-alkylated steroid-induced ALT elevation. This has never been tested in humans. The AAS hepatotoxicity signal is large and noisy; any BPC-157 effect would be invisible behind it.

Healthy users on BPC-157 alone:

• ALT is expected to stay at baseline (no published human data showing change).
• Lee & Burgess 2025 saw no shift at 20 mg IV in 2 subjects.
• Standard subcutaneous protocols (250-500 mcg/day) are well below the IV dose tested.

BPC-157 stacked with hepatotoxic AAS (dianabol, anadrol, halotestin):

• Rat models suggest BPC-157 may blunt ALT elevation, but the human prediction is uncertain.
• ALT typically rises 2-5x ULN on oral AAS regardless of co-administered peptides.
• Do not assume BPC-157 is "protecting" the liver. The signal-to-noise ratio is too low to detect any peptide effect against AAS-driven enzyme elevation.
• The vendor narrative that BPC-157 "lets you run orals longer or harder" has no evidence support and is harm-reduction red flag thinking.

BPC-157 stacked with TRT alone (no orals):

• ALT should remain at baseline. TRT does not meaningfully elevate ALT in most users.
• Any ALT rise on a BPC-157 plus TRT protocol warrants the same workup as ALT rise without BPC-157.

Baseline: Standard liver panel before starting BPC-157 (ALT, AST, GGT, total bilirubin). Establishes your individual reference.

Week 4: Repeat the panel. If ALT has changed, the cause is almost certainly a co-administered compound (AAS, alcohol, NSAID use, infection), not the peptide.

Week 12 or cycle end: Repeat the panel. Compare to baseline.

When BPC-157 is stacked with AAS: monitoring frequency follows the AAS schedule, not the peptide. Every 4-6 weeks on cycle for 17-alpha-alkylated orals.

The diagnostic key: pair ALT with GGT. If GGT is normal but ALT is elevated, the source may be muscle (training noise, AST/ALT ratio above 1). If GGT is elevated alongside ALT, hepatic origin is confirmed. BPC-157 has no documented effect on GGT in humans.

If ALT rises on a BPC-157 plus AAS stack, blame the steroid first. The prior probability that the oral AAS is responsible vastly outweighs the probability that the peptide is. The order of operations:

• Recheck ALT, AST, GGT, total bilirubin within 2 weeks.
• If hepatic pattern is confirmed (ALT and GGT both elevated, AST/ALT ratio below 1, bilirubin trending up), reduce or stop the oral AAS first.
• Hold the peptide only if you want to isolate variables for diagnostic clarity, or if you suspect a contaminated batch.
• Do not attribute ALT elevation to BPC-157 without ruling out every co-administered compound, recent training intensity, and alcohol intake.

If ALT rises on BPC-157 alone (no AAS):

• This is uncommon and the human literature offers no precedent.
• Consider contaminated product, lot-specific issues, or a coincidental cause (viral hepatitis, NSAID load, alcohol).
• Hold the peptide and recheck in 2-4 weeks. If ALT normalises, you have a cause-effect signal worth respecting.
• If ALT continues to rise after stopping, look elsewhere.

Do not stack BPC-157 expecting hepatoprotection from oral AAS. The case for protection is rat-derived. Standard AAS harm-reduction (TUDCA 500-1000 mg/day, NAC 600-1200 mg/day, limiting oral duration, dose moderation) has more human evidence than BPC-157.